692
Participants
Start Date
August 1, 2023
Primary Completion Date
August 30, 2024
Study Completion Date
August 30, 2024
CV0701 mRNA COVID-19 Vaccine (Low dose)
Study vaccine was administered as a single intramuscular injection.
CV0701 mRNA COVID-19 Vaccine (Medium dose)
Study vaccine was administered as a single intramuscular injection.
CV0701 mRNA COVID-19 Vaccine (High dose)
Study vaccine was administered as a single intramuscular injection.
CV0601 mRNA COVID-19 Vaccine
Study vaccine was administered as a single intramuscular injection.
Control vaccine
Study vaccine was administered as a single intramuscular injection.
CV0801 mRNA COVID-19 Vaccine
Study vaccine was administered as a single intramuscular injection.
GSK Investigational Site, Darlinghurst
GSK Investigational Site, Botany
GSK Investigational Site, Maroubra
GSK Investigational Site, Brookvale
GSK Investigational Site, Blacktown
GSK Investigational Site, Kanwal
GSK Investigational Site, Merewether
GSK Investigational Site, Coffs Harbour
GSK Investigational Site, Bruce
GSK Investigational Site, Camberwell
GSK Investigational Site, Blacktown
GSK Investigational Site, Sherwood
GSK Investigational Site, Tarragindi
GSK Investigational Site, Adelaide
GSK Investigational Site, Hollywood
GSK Investigational Site, Sacramento
GSK Investigational Site, Peoria
Lead Sponsor
Collaborators (1)
CureVac
INDUSTRY
GlaxoSmithKline
INDUSTRY